Viz.ai’s software has been designed to detect suspected large vessel occlusion (LVO) strokes and alert specialists. Credit: Gerd Altmann from Pixabay.

Irish medical technology firm Medtronic has agreed to distribute artificial intelligence (AI)-based stroke care solutions provider Viz.ai’s new technology across US centres.

Viz.ai’s software, which holds US Food and Drug Administration (FDA) clearance, has been designed to detect suspected large vessel occlusion (LVO) strokes.

It can be linked to hospital computed tomography (CT) scanners and uses advanced deep learning to automatically notify specialists about a suspected LVO stroke.

Within minutes, the software sends radiological images directly to stroke specialists’ smartphones.

The technology is expected to optimise stroke care and decrease time-to-treatment for better patient outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the terms of the deal, Medtronic will distribute Viz.ai’s LVO detection and triage software services that have marketing authorisation in the US.

Viz.ai technology is available in more than 200 hospitals and aims to expand to all stroke centres.

Viz.ai co-founder and CEO Dr Chris Mansi said: “As the largest medical device company in the world, Medtronic is an ideal partner to help physicians access Viz.ai’s cutting-edge technology to ensure as many patients get the care they need as quickly as possible.”

Of all patients who suffer from an LVO in the US, only 15% are estimated to undergo a mechanical thrombectomy procedure that removes blood clots, noted Medtronic.

In a study conducted at two sites, Viz LVO demonstrated the ability to alert the stroke specialist earlier than standard in 95.5% of true positive cases. The software was able to save an average of 52 minutes.

Medtronic Neurovascular business vice-president and general manager Stacey Pugh said: “We are excited about this partnership because Viz.ai’s technology has the potential to significantly reduce the time it takes for patients suspected of LVO stroke to receive the care they need.

“Viz.ai’s software coupled with our network is going to increase access to needed therapies. It greatly complements our existing portfolio.”

Currently, the Irish company provides the Solitaire Platinum revascularisation stent designed to retrieve clots from occluded blood vessels in the brain of patients having an acute ischemic stroke (AIS) due to an LVO.